WHO terms obesity ‘global health crisis’, backs long-term use of GLP-1 drugs, Pg2

Key Highlights:

• The WHO has termed obesity a "global health crisis" and released its first guidelines on using GLP-1 medicines for treatment.
• The guidelines recommend long-term use of GLP-1 therapies alongside intensive behavioral therapy.
• Globally, 1 billion people live with obesity, including 188 million children and adolescents.
• The WHO estimates that obesity rates will double by 2030 if the crisis is not addressed.
• There are currently 12 GLP-1 therapies approved for treating obesity or type-2 diabetes, with 40 more in development.
• The WHO emphasizes the need for equitable access to GLP-1 medicines, addressing issues like high costs and limited production.

Detailed Insights:

• Obesity is now recognized as a chronic disease requiring lifetime care, necessitating comprehensive treatment approaches.
• GLP-1 therapies can aid in overcoming obesity and reducing associated harms, but medication alone is insufficient.
• The WHO supports long-term use of GLP-1 medicines in adults (excluding pregnant women) but acknowledges limited data on long-term effects.
• Equitable access to GLP-1 therapies is crucial, but current production could only cover less than 10% of people with obesity.
• High costs, limited production capacity, and supply-chain issues are major barriers to universal access to these therapies.
• The WHO proposes manufacturing generic versions of GLP-1 drugs and pre-qualification to enhance international access.
• Inclusion of GLP-1 medicines in the WHO list of essential medicines aims to ensure wider availability in healthcare settings.

Key Concepts Involved:

• Obesity: A chronic disease characterized by excessive body fat accumulation, posing significant health risks.
• GLP-1 Therapies: Medications that mimic the glucagon-like peptide-1 hormone, used to treat diabetes and obesity.
• Comorbidities: Co-existing medical conditions or diseases that occur simultaneously with another condition.